Protagonist Therapeutics Reports Q2 2025 Financial Results with Increased License Revenue and Net Loss

Protagonist Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a license and collaboration revenue of $5.5 million, a 33% increase from $4.2 million in the same period last year. However, the company experienced a significant decline in total revenue for the first half of 2025, reporting $33.9 million compared to $259.1 million in the first half of 2024, primarily due to the recognition of a $300 million upfront payment from Takeda in 2024. The company incurred a net loss of $34.8 million for the quarter, compared to a loss of $30.6 million in the prior year, reflecting an increase in operating expenses driven by research and development costs.

Total operating expenses for the second quarter of 2025 reached $47.6 million, an 11% increase from $43.0 million in the same quarter of 2024. Research and development expenses rose by 10% to $37.0 million, largely due to increased spending on pre-clinical and drug discovery programs, including candidates PN-881 and PN-477. General and administrative expenses also increased by 12% to $10.6 million, attributed to higher personnel-related costs. The company’s accumulated deficit as of June 30, 2025, stood at $386.9 million, reflecting ongoing investments in its clinical programs.

In terms of strategic developments, Protagonist is advancing its two lead product candidates, icotrokinra and rusfertide, both in Phase 3 clinical trials. The company submitted a New Drug Application (NDA) for icotrokinra to the FDA in July 2025, while rusfertide is being co-developed with Takeda, with an NDA filing expected in the fourth quarter of 2025. The company has also made significant progress in its collaboration agreements, having earned a total of $337.5 million in non-refundable payments from JNJ since the inception of their partnership in 2017.

Operationally, Protagonist reported a cash position of $673 million as of June 30, 2025, an increase from $559.2 million at the end of 2024. The company’s cash flow from operating activities for the first half of 2025 was $96.6 million, primarily driven by a milestone payment received from JNJ. The company’s employee headcount increased slightly, with 100 full-time equivalent employees in research and development and 30 in general and administrative roles as of June 30, 2025.

Looking ahead, Protagonist anticipates continued investment in its research and development programs, particularly as it prepares for regulatory filings and commercialization efforts for rusfertide. The company expects to incur additional losses as it advances its clinical trials and seeks to bring its product candidates to market. Protagonist's management remains optimistic about the potential for future milestone payments and royalties from its collaboration agreements, which will be critical for funding ongoing operations and development activities.